The ASA has prohibited a billboard advert for a £49 facial serum after ruling that claims it might enable users look up to five years younger were deceptive and unproven. The poster for Eucerin Hyaluron-Filler Epigenetic Serum, which was displayed at Balham tube station in London, stated the product was “clinically proven” founded on a study of 160 people. However, the regulator found significant flaws in the study design, such as the absence of a control group and dependence on subjective self-assessment from participants. The complaint was filed in November 2025, triggering the ASA investigation that ultimately judged the advert deceptive and banned it from appearing in its current form.
The Prohibited Campaign and Its Controversial Claims
The Eucerin advertisement depended significantly on a four-week study featuring 160 individuals who were simply asked to provide self-reported accounts of how much younger they felt they looked after using the serum. This research approach raised immediate red flags for the ASA, which identified several critical weaknesses in the study design. Particularly important, the study did not include a comparison group—a fundamental requirement in scientific research that would have allowed researchers to assess outcomes against a reference point. The absence of such controls meant there was no means to determine whether any apparent benefits were truly due to the serum or merely the result of placebo effect, inherent skin differences, or additional outside influences.
Beiersdorf, the organisation behind Eucerin, attempted to justify the “up to five years younger” claim by contending it represented a genuine maximum result rather than a standard result. However, the ASA’s reservations extended past the main investigation. The watchdog highlighted that the serum had been evaluated in a different geographical region to the United Kingdom, raising questions about whether findings would apply to British consumers. Additionally, three supporting items of evidence submitted by Beiersdorf consisted entirely of unpublished studies, whilst a fourth piece—a study that had been peer-reviewed on the active ingredient—did not even evaluate the serum itself, further undermining the substantiation for the ambitious anti-ageing assertions.
- Study was missing comparative baseline to establish actual product efficacy
- Self-reporting by participants generated reporting bias into findings
- Testing conducted in different climate than British market
- Supporting evidence predominantly unpublished and methodologically questionable
Regulatory Concerns and Problematic Approach
Why the Investigation Failed Requirements
The ASA’s investigation exposed fundamental flaws in how Beiersdorf executed and communicated its research. The lack of clear recruitment information ensured the watchdog could not verify whether participants were truly reflective of the broader consumer base or if selection bias had distorted findings towards favourable outcomes. Without knowing how volunteers were recruited, whether they had existing familiarity with skincare products, or if they maintained brand preference for the brand, the trustworthiness of their feedback became deeply problematic. These research limitations are precisely the kind that watchdog organisations scrutinise when evaluating claims that could influence purchasing decisions.
Self-reporting by study participants introduced a significant layer of subjective bias into the findings. Asking individuals to estimate how many years younger they appeared is fundamentally problematic, as perceptions of ageing are highly individual and influenced by mental processes, lighting conditions, and individual expectations. The ASA rightly questioned whether participants’ responses represented actual physical alterations or merely their hopes and beliefs about the product’s efficacy. This distinction holds significant weight when a company seeks to market a £49 serum as “clinically proven”—a phrase suggesting rigorous, objective scientific validation rather than individual subjective views.
- No control group meant impossible to isolate the actual effects
- Selection methodology not revealed, creating selection bias concerns
- Subjective self-assessment cannot provide clinical proof of efficacy
- Varying environmental conditions weakened applicability to UK consumers
- Supporting evidence mostly undisclosed, restricting third-party scrutiny
Widespread Issue with Beauty Advertising
The Eucerin serum ban is simply the latest in a pattern of false assertions that has affected the cosmetics advertising industry for years. Beauty companies have repeatedly pushed the limits of permissible marketing language, leveraging aspirational messaging and scientific-sounding terminology to persuade consumers that products deliver dramatic outcomes. Lianne Sykes, an marketing specialist in aesthetics who advises firms on ethical advertising practices, stresses that this issue is widespread rather than being isolated. Companies often prioritise compelling marketing narratives over thorough evidence, banking on the assumption that consumers will not examine claims too closely or that regulatory enforcement will be slow.
The cosmetics market capitalises on inherent appetite for noticeable enhancements in appearance, creating fertile ground for overstated claims. When companies use phrases like “clinically proven” without satisfying the rigorous requirements that such language demands, they undermine the trust customers put in scientific terminology. The ASA’s results suggest that Beiersdorf’s approach—submitting unpublished research, carrying out studies in unsuitable climates, and depending on subjective self-assessment—constitutes a worrying but not uncommon strategy. Without consistent enforcement and improved disclosure from suppliers, consumers stay susceptible to marketing claims that prioritise sales over honesty.
What Consumers Should Question
Rather than accepting beauty product claims uncritically, consumers should cultivate a more discerning approach to scrutinising cosmetic advertising. Sykes recommends asking fundamental questions prior to buying, notably when companies put forward assertions about noticeable outcomes. Understanding the testing methods used, who features in studies, and what measures are measured can reveal whether claims rest on solid evidence or marketing spin. Consumers must acknowledge that good skin generally stems from consistent habits and one’s natural biology rather than dependence on a one wonder product, no matter its price point or branding.
- How is skin quality systematically assessed and evaluated over time?
- Were trials conducted on varied age ranges and skin types?
- Is the evidence published and independently verifiable by scientists?
- Does the test conditions match actual conditions where consumers live?
Beiersdorf’s Reaction and Forthcoming Consequences
Beiersdorf, the German multinational corporation behind the Eucerin brand, has maintained that its products are underpinned by legitimate scientific research conducted in accordance with industry standards. The company justified its choice to state the claim as “up to” five years younger, contending this phrasing correctly captured the true maximum outcome detected rather than a typical outcome. However, the ASA’s detailed scrutiny of the research approach—including the lack of a control group, absence of clarity about participant recruitment, and reliance on subjective self-reporting—suggests that sector guidelines by themselves may be insufficient to protect consumers from false claims.
The ban signals a broader shift in regulatory enforcement targeting cosmetics advertising, though questions remain about whether isolated cases translate into systemic change. Beiersdorf stated that the billboard advertisement is no longer active in the UK, but the ruling highlights key concerns about how widely similar claims persist across other products and promotional platforms. If enforcement continues at this pace, companies may face increasing demands to commit resources to genuinely robust clinical evidence rather than depending on the vagueness surrounding unsubstantiated findings. For consumers, this case highlights the importance of requiring openness and scrutinising even well-established brands.